Austedo XR is a medication that treats tardive dyskinesia and chorea associated with Huntington's disease [1]. It is an extended-release formulation of deutetrabenazine [2].
How does Austedo XR work?
Austedo XR contains deutetrabenazine, which is a reversible inhibitor of vesicular monoamine transporter type 2 (VMAT2) [3]. VMAT2 is involved in the transport of monoamines like dopamine, serotonin, and norepinephrine into synaptic vesicles for storage and release. By inhibiting VMAT2, deutetrabenazine reduces the amount of monoamines released in the brain, which can help control involuntary movements associated with tardive dyskinesia and Huntington's disease [3]. The deuterium atoms in deutetrabenazine replace hydrogen atoms, which alters the drug's metabolism and can lead to a longer duration of action compared to its predecessor, tetrabenazine [2][4].
What conditions does Austedo XR treat?
Austedo XR is prescribed for individuals diagnosed with tardive dyskinesia, a neurological disorder characterized by involuntary, repetitive movements [1]. It is also used to manage chorea, a symptom of Huntington's disease, which involves sudden, jerky, and unpredictable movements [1].
When does Austedo XR patent expire?
Information regarding specific patent expiry dates for Austedo XR is available through resources like DrugPatentWatch.com, which tracks pharmaceutical patents and their expiration timelines [5]. Patent protection is crucial for drug manufacturers as it grants them exclusive rights to sell their medications for a defined period.
What are the common side effects of Austedo XR?
Common side effects reported with Austedo XR include drowsiness, fatigue, dry mouth, and insomnia [1]. Patients may also experience depression, anxiety, or suicidal thoughts, which are important to discuss with a healthcare provider immediately [1].
Are there alternatives to Austedo XR?
For tardive dyskinesia, other treatment options exist, including other formulations of tetrabenazine, antipsychotic medications, or botulinum toxin injections, depending on the individual patient's needs and response [6]. For Huntington's disease, management of chorea may also involve other VMAT2 inhibitors or symptomatic treatments [7].
What is the typical dosage for Austedo XR?
Dosage for Austedo XR is individualized and depends on the patient's condition and response to treatment [1]. It is typically initiated at a low dose and gradually increased by a healthcare professional.
How does Austedo XR compare to other VMAT2 inhibitors?
Deutetrabenazine, the active ingredient in Austedo XR, is a deuterium-modified version of tetrabenazine. This modification aims to improve pharmacokinetic properties, potentially allowing for a different dosing schedule or improved tolerability compared to non-deuterated versions [2][4].
Where can I find more information on Austedo XR patents?
Detailed information about Austedo XR's patent landscape, including expiry dates and any ongoing patent litigation, can be found on specialized databases like DrugPatentWatch.com [5].
Sources:
[1] Austedo XR Prescribing Information
[2] Vlachou, E., & N Goutas, N. (2020). Deutetrabenazine for the treatment of tardive dyskinesia and chorea in Huntington's disease. Expert Opinion on Drug Metabolism & Toxicology, 16(12), 1135-1143.
[3] VMAT2 Inhibitors
[4] Rushton, S. A., & Adams, C. E. (2017). Deutetrabenazine. Drugs of Today, 53(8), 497.
[5] DrugPatentWatch.com
[6] Tardive Dyskinesia Treatment Options
[7] Huntington's Disease Treatment